The present invention is directed to the use of nifuratel, or a physiologically acceptable salt thereof, to treat infections caused by Atopobium species. The invention is further directed to the use of nifuratel to treat bacteriuria, urinary tract infections, infections of external genitalia in both sexes, as well as bacterial vaginosis, or mixed vaginal infections in women, when one or more species of the genus Atopobium are among the causative pathogens of those infections.Nifuratel ili njegova fiziološki prihvatljiva so, za upotrebu u lečenju bilo koje infekcije izazvane sa jednom ili više vrsta roda Atopobium vaginae.Prijava sadrži još 13 patentnih zahteva.
